Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioma 8Rhabdoid Tumor 7Osteosarcoma 7Neuroblastoma 7Medulloblastoma 7Lung Neoplasms 7Wilms Tumor 6Sarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Neoplasm Metastasis 6Lymphoma, Non-Hodgkin 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Ependymoma 6Central Nervous System Neoplasms 6Rhabdomyosarcoma 5Lymphoma 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Multiple Myeloma 4Colorectal Neoplasms 4Small Cell Lung Carcinoma 3Sarcoma, Ewing 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Leukemia, Myeloid, Acute 3Stomach Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2

Interventions

Nivolumab 5Specimen Handling 4Magnetic Resonance Spectroscopy 4Radiotherapy 3Mitomycin 3Fluorouracil 3Biopsy 3fludarabine phosphate 2fludarabine 2entinostat 2aldesleukin 2Trastuzumab 2Sigmoidoscopy 2Proctoscopy 2Ipilimumab 2Interleukin-12 Subunit p35 2Erlotinib Hydrochloride 2Cyclophosphamide 2Colonoscopy 2CTLA-4 Antigen 2tipifarnib 1tempol 1oncogene protein E7, Human papillomavirus type 16 1dehydroftorafur 1bintrafusp alfa protein, human 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Taxes 1Serotonin Plasma Membrane Transport Proteins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Anus Neoplasms × X-Rays × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡